NCT03732833

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 425 (actual)
• Sponsor: Medy-Tox · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.

Conditions

• Lateral Canthal Lines
• Glabellar Lines

Interventions

Type	Name	Description
DRUG	MT10109L	MT10109L will be injected into either the LCL, or both the LCL and GL.
DRUG	Placebo	Placebo will be injected into either the GL, or both the LCL and GL.

Timeline

• Start date: 2018-11-05
• Primary completion: 2020-03-05
• Completion: 2021-01-25
• First posted: 2018-11-07
• Last updated: 2023-07-17
• Results posted: 2023-07-17

Locations

20 sites across 3 countries: United States, Canada, Germany

Regulatory

• FDA-regulated drug study